Griffin: Accessing functional antibodies from serum without B cells
Griffin is a platform for sequencing polyclonal antibodies using mass spectrometry. Since 2009, Abterra Biosciences founders and employees have been developing novel methods for sequencing antibody proteins directly. Our monoclonal antibody sequencing service, Valens, has been used to successfully sequence hundreds of antibodies without the need for B cells. Now, with Griffin, we can sequencing complex mixes of antibodies directly from patient serum, or from immunized animals.
Watch our CEO, Dr. Natalie Castellana’s presentation on Unlocking the Serum Antibody Repertoire: Accessing Functional Antibodies without B Cells to learn how Griffin works.
Click below to watch the presentation.
Related Posts
Hybridoma Sequencing Pitfalls: 3 Top Lessons Learned
MotivationSince the technology's invention in 1975, hybridomas have been a favored method of monoclonal antibody production. By fusing immortal myeloma cells with antibody producing B cells in culture, hybridomas can deliver a nearly infinite supply of antibodies....
Human Antibody Sequencing from Serum
MotivationHuman antibody sequencing is a powerful tool for understanding the humoral immune response. Until recently, B cell-focused approaches have been the only available tool for understanding the diversity and plasticity of the antibody response to challenge (see...
De Novo Antibody Sequencing: Which Enzymes are Best?
De novo antibody sequencing is the process of determining the primary amino acid sequence of an antibody directly from the protein. Determining the sequence of an antibody is a requirement for many downstream activities. Intellectual Property Protection: In order to...
Get In Touch